<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pioglitazone and glimepiride: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pioglitazone and glimepiride: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pioglitazone and glimepiride: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11829" href="/d/html/11829.html" rel="external">see "Pioglitazone and glimepiride: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709213"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Congestive heart failure:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones, including pioglitazone, cause or exacerbate congestive heart failure (CHF) in some patients. After initiation of pioglitazone/glimepiride, observe patients carefully for signs and symptoms of heart failure (including excessive, rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop, manage the heart failure according to the current standards of care. Furthermore, consider discontinuation of pioglitazone/glimepiride.</p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone/glimepiride is not recommended in patients with symptomatic heart failure. Initiation of pioglitazone/glimepiride in patients with established New York Heart Association (NYHA) class III or IV heart failure is contraindicated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F3340525"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Duetact</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F3340529"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiabetic Agent, Sulfonylurea;</li>
<li>
                        Antidiabetic Agent, Thiazolidinedione</li></ul></div>
<div class="block doa drugH1Div" id="F3340558"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> May require a dose reduction of other insulin secretagogues (sulfonylureas, meglitinides) to avoid hypoglycemia; consider stopping insulin or reducing insulin dose (eg, by 10% to 25%) (ADA/EASD [Davies 2018]; manufacturer's labeling).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Additional therapeutic considerations may apply; refer to individual agents for information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial dose should be based on current dose of pioglitazone and/or sulfonylurea.</p>
<p style="text-indent:-2em;margin-left:6em;">Patients inadequately controlled on <b>glimepiride</b> alone: Initial dose: Pioglitazone 30 mg/glimepiride 2 mg or pioglitazone 30 mg/glimepiride 4 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Patients inadequately controlled on <b>pioglitazone</b> alone: Initial dose: Pioglitazone 30 mg/glimepiride 2 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Patients currently on sulfonylurea monotherapy (other than glimepiride) or switching from combination therapy of pioglitazone plus a sulfonylurea (other than glimepiride): Initial: Pioglitazone 30 mg/glimepiride 2 mg once daily. When converting patients from other sulfonylureas with longer half-lives (eg, chlorpropamide) to glimepiride, observe patient carefully for 1 to 2 weeks due to overlapping hypoglycemic effects.</p>
<p style="text-indent:-2em;margin-left:6em;">Patients with systolic dysfunction (eg, NYHA Class I and II): Initiate only after patient has been safely titrated to 30 mg of pioglitazone. Initial dose: Pioglitazone 30 mg/glimepiride 2 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment:</b> Dosage may be increased up to a maximum dose of pioglitazone 45 mg/glimepiride 8 mg once daily based on effectiveness and tolerability. Dosage adjustments in patients with systolic dysfunction should be done carefully and patient monitored for symptoms of worsening heart failure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991026"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer’s labeling; initiate and adjust dose conservatively; observe carefully for hypoglycemia.</p></div>
<div class="block doha drugH1Div" id="F50988241"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment prior to initiation: There are no specific dosage adjustments provided in the manufacturer’s labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment during therapy: If liver injury is suspected (eg, fatigue, jaundice, dark urine): Interrupt therapy, measure serum liver tests, and investigate possible etiologies:</p>
<p style="text-indent:-2em;margin-left:4em;">If an alternative etiology is not identified and ALT &gt;3 x ULN: Do not reinitiate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">If an alternative etiology is identified and ALT elevated (but &lt;3 x ULN) <b>or</b> total bilirubin elevated (but &lt;2 x ULN): May reinitiate with caution.</p></div>
<div class="block doe drugH1Div" id="F3340559"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Use of sulfonylureas (eg, glimepiride) is associated with increased risk of hypoglycemia. The American Diabetes Association suggests using sulfonylureas with caution, and notes preference for glimepiride (or glipizide) due to lower relative risk of hypoglycemia compared to other sulfonylureas (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.1'])">Ref</a></span>). If used, initiate and adjust dose conservatively; observe carefully for hypoglycemia. Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F3340540"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for glimepiride. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (≤12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (13% to 16%), weight gain (9% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (12% to 17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (≤7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (4% to 6%), nausea (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (6% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (4% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Heart failure (including worsening of heart failure)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Genitourinary: Bladder carcinoma (FDA 2016)</p></div>
<div class="block coi drugH1Div" id="F3340536"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to glimepiride, pioglitazone, or any component of the formulation; history of allergic reaction to sulfonamide derivatives; NYHA Class III/IV heart failure (initiation of therapy).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged. See “Warnings/Precautions” for more detail.</p></div>
<div class="block war drugH1Div" id="F3340537"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bladder cancer: An FDA review concluded that, although clinical trial data are inconsistent regarding the risk of bladder cancer in patients exposed to pioglitazone, there is still the potential for an increased risk and package labeling has been updated to reflect this. Avoid use of pioglitazone in patients with active bladder cancer and consider risks vs. benefits prior to initiating therapy in patients with a history of bladder cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS 1998), have not supported an association. In a prospective, active-controlled study comparing linagliptin to glimepiride in patients with high baseline cardiovascular risk, the rates of cardiovascular events were similar over ~6 years (Rosenstock 2019). In patients with established atherosclerotic cardiovascular disease, other agents (eg, with demonstrated cardiovascular risk reduction) are preferred (ADA 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• Edema: Dose-related edema, including new-onset or exacerbation of existing edema, has been reported with pioglitazone; use with caution in patients with edema. Monitor for signs/symptoms of heart failure (HF).</p>
<p style="text-indent:-2em;margin-left:4em;">• Fractures: An increased incidence of bone fractures has been observed in females treated with pioglitazone; majority of fractures occurred in the lower limb and distal upper limb. Consider risk of fracture prior to initiation and during use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure/cardiac effects: <b>[US Boxed Warning]: Thiazolidinediones, including pioglitazone, may cause or exacerbate HF; closely monitor for signs and symptoms of HF (eg, rapid weight gain, dyspnea, edema), particularly after initiation or dose increases; if HF develops, treat accordingly and consider dose reduction or discontinuation. Not recommended for use in any patient with symptomatic HF; initiation of therapy is contraindicated in patients with New York Heart Association (NYHA) class III or IV HF.</b> If used in patients with NYHA class I or II (systolic) HF, initiate at lowest dosage and monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Pioglitazone may decrease hemoglobin/hematocrit; effects may be related to increased plasma volume.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Hepatic failure, including fatalities, has been reported with pioglitazone use. Monitor for signs/symptoms of liver injury closely during therapy; discontinuation of therapy may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions to glimepiride (eg, cutaneous eruptions, anaphylaxis, angioedema, Stevens-Johnson syndrome [SJS]) have occurred. If hypersensitivity reactions occur, discontinue use immediately and institute alternative treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients and in patients with impaired renal or hepatic function; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Macular edema: Has been reported with thiazolidinedione use, including pioglitazone; some patients with macular edema presented with blurred vision or decreased visual acuity, and most had peripheral edema at time of diagnosis. Patients should be seen by an ophthalmologist if any visual symptoms arise during therapy and all diabetic patients should have regular eye exams.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide (“sulfa”) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, 2 antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (SJS/toxic epidermal necrolysis), some clinicians choose to avoid exposure to these classes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Weight gain: Dose-related weight gain observed with pioglitazone use; mechanism unknown but likely associated with fluid retention and fat accumulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Altered absorption: Absorption may be altered given the anatomic and transit changes created by gastric bypass and sleeve gastrectomy surgery (Mechanick 2020; Melissas 2013). Use IR formulations after surgery to minimize the potential effects of bypassing stomach and proximal small bowel with gastric bypass or more rapid gastric emptying and proximal small bowel transit with sleeve gastrectomy (Apovian 2015). ER formulations may have altered release and absorption patterns after gastric bypass or sleeve gastrectomy (but not gastric band). Compared to control, T<sub>max</sub> in a gastric bypass cohort administered tolbutamide was significantly shorter (1.4 ± 1.8 vs 5.1 ± 1.7 hours; <i>P </i>&lt; 0.001) while C<sub>max</sub> and AUC<sub>0-</sub>
<sub>∞</sub> were not altered (Tandra 2013).</p>
<p style="text-indent:-2em;margin-left:6em;">– Hypoglycemia: Use an antidiabetic agent without the potential for hypoglycemia if possible; hypoglycemia may occur after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020). Insulin secretion and sensitivity may be partially or completely restored after these procedures (gastric bypass is most effective, followed by sleeve and finally band) (Korner 2009; Peterli 2012). First-phase insulin secretion and hepatic insulin sensitivity have been shown to be significantly improved in the immediate days after gastric bypass and sleeve gastrectomy. The restorative effects of these procedures on peripheral insulin sensitivity may occur later in the 3- to 12-month period postsurgery (Mingrone 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">– Weight gain: Evaluate risk vs benefit and consider alternative therapy after gastric bypass, sleeve gastrectomy, and gastric banding; weight gain may occur (Apovian 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose-6-phosphate dehydrogenase deficiency: Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Due to the possible risk of drug-induced liver injury with pioglitazone, serum LFTs (ALT, AST, alkaline phosphatase, and total bilirubin) should be obtained prior to initiation in all patients. In patients with abnormal hepatic tests, therapy should be initiated with caution. During therapy, if signs/symptoms of liver injury (eg, fatigue, anorexia, jaundice, dark urine, right upper abdominal discomfort) arise, interrupt pioglitazone therapy, obtain liver tests immediately and evaluate alternative etiologies. If an alternative etiology is not identified and serum ALT is &gt;3 times ULN, do not resume therapy. Patients with serum ALT &gt;3 times ULN and serum total bilirubin &gt;2 times ULN are at risk for severe drug-induced liver injury. Risk of hypoglycemia may be increased in patients with hepatic impairment and receiving glimepiride.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal function impairment: Use glimepiride with caution; patients with renal impairment are more likely to develop hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2C9 genotype: Systemic exposure of glimepiride is increased in patients with CYP2C9*3 allele (Niemi 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution; elderly patients are more likely to develop hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for use in patients with diabetic ketoacidosis or patients with type 1 diabetes mellitus.</p></div>
<div class="block foc drugH1Div" id="F3340566"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: 30/2: Pioglitazone 30 mg and glimepiride 2 mg; 30/4: Pioglitazone 30 mg and glimepiride 4 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Duetact:</p>
<p style="text-indent:-2em;margin-left:6em;">30 mg/2 mg: Pioglitazone 30 mg and glimepiride 2 mg</p>
<p style="text-indent:-2em;margin-left:6em;">30 mg/4 mg: Pioglitazone 30 mg and glimepiride 4 mg </p></div>
<div class="block geq drugH1Div" id="F3340527"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F4370391"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Duetact Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30-2 mg (per each): $23.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30-4 mg (per each): $23.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Pioglitazone HCl-Glimepiride Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30-2 mg (per each): $15.62 - $16.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30-4 mg (per each): $15.62 - $16.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F3340562"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer once daily with the first main meal of the day. To avoid hypoglycemia, patients without oral intake may need to have the dose held. </p></div>
<div class="block meg drugH1Div" id="F9350996"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F021925s017lbl.pdf%23page%3D39&amp;token=0xArWZkun6glelWIj5kLrHbuBopaXRzPmHsjavLPiFEN3fdm5pGZr%2FBsVNyMUlwLdxz34vT19h5Duj%2FJPl38HfaZn5UvXR6jys%2BjM492imaUehd9mxfarLxNixrGlGJ3&amp;TOPIC_ID=9477" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021925s017lbl.pdf#page=39</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F3340530"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diabetes mellitus, type 2, treatment:</b> As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and glimepiride is appropriate.</p></div>
<div class="block mst drugH1Div" id="F5174559"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes glimepiride among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Avoid routine use of sulfonylureas due to increased risk of hypoglycemia. If a sulfonylurea is needed, one with a lower relative risk of hypoglycemia (eg, glimepiride, glipizide) is preferred (ADA 2021; Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F3340547"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F3340546"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: May enhance the hypoglycemic effect of Thiazolidinediones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Glucosidase Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with an alpha-glucosidase inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Sulfonylureas. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbocisteine: Sulfonylureas may enhance the adverse/toxic effect of Carbocisteine. Specifically, sulfonylureas may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colesevelam: May decrease the serum concentration of Glimepiride. Management: Administer glimepiride at least 4 hours prior to colesevelam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inducers (Moderate): May decrease the serum concentration of Pioglitazone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Moderate): May increase the serum concentration of Pioglitazone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Strong): May increase the serum concentration of Pioglitazone. Management: Limit the pioglitazone dose to 15 mg daily and monitor for increased pioglitazone toxicities (eg, hypoglycemia) when used in combination with strong CYP2C8 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inducers (Moderate): May decrease the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: May increase the serum concentration of Glimepiride.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May enhance the adverse/toxic effect of Thiazolidinediones. Specifically, the risk of osteoporosis or fracture may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Pioglitazone may enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination.  Management: If insulin is combined with pioglitazone, consider insulin dose reductions to avoid hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure, and consider pioglitazone dose reduction or discontinuation if heart failure occurs<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metreleptin: May enhance the hypoglycemic effect of Sulfonylureas. Management: Sulfonylurea dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely for signs or symptoms of hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Miconazole (Oral): May enhance the hypoglycemic effect of Sulfonylureas. Miconazole (Oral) may increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitiglinide: May enhance the adverse/toxic effect of Sulfonylureas.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pregabalin: May enhance the fluid-retaining effect of Thiazolidinediones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 (SGLT2) inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonamide Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Thiazolidinediones may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: May increase the serum concentration of Glimepiride.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May decrease the serum concentration of Pioglitazone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F3340548"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;display:inline">See individual agents</p></div>
<div class="block rep_considerations drugH1Div" id="F49321386"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pioglitazone may increase ovulation in premenopausal anovulatory patients resulting in unintended pregnancies.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block pri drugH1Div" id="F3340532"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">If exposure during pregnancy occurs, discontinue at least 2 weeks prior to expected delivery.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for information related to the treatment of diabetes mellitus in pregnancy.</p></div>
<div class="block brc drugH1Div" id="F3340535"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if glimepiride or pioglitazone is excreted in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block mop drugH1Div" id="F3340564"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Serum glucose.</p>
<p style="text-indent:-2em;margin-left:2em;">HbA<sub>1c</sub>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2021; KDIGO 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Liver enzymes (ALT, AST, alkaline phosphatase, and total bilirubin) prior to initiation in all patients (with or without liver disease); continue routine periodic monitoring during treatment only in patients with liver disease or suspected liver disease.</p>
<p style="text-indent:-2em;margin-left:2em;">Signs and symptoms of heart failure; weight gain; signs/symptoms of bladder cancer (dysuria, macroscopic hematuria, dysuria, urinary urgency); ophthalmic exams.</p></div>
<div class="block rer drugH1Div" id="F3340553"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults with diabetes (AACE [Samson 2023]; ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b> Note: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (LeRoith 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note:</b> Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F3340551"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone: A thiazolidinedione that lowers blood glucose by improving target cell response to insulin, without increasing pancreatic insulin secretion. It has a mechanism of action that is dependent on the presence of insulin for activity.</p>
<p style="text-indent:-2em;margin-left:2em;">Glimepiride: A sulfonylurea that stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites.</p></div>
<div class="block phk drugH1Div" id="F3340554"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539980"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Duetact</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Tandemact</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Dieta Plus | Tosirin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amaglust | Glimepiride plus | Piompride | Zanoglide</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Tandemact</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adride p | Dibiglim-p | Euglim-p | G-tase g | Glimiprex-pg | Glimtaz | Glimy-p | K-pio-g | Normaglim P | Piobeta | Pioglar g | Pioglar gf | Pioglit-g | Pionorm-g | Pioride | Pioryl | Piotop ud | Pioz g | Piozone g | Zorep</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Tandemact</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Duetact</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Actosryl</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Duetact</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Diaberil | Novoberil</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Zorep</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Asenza plus | Zoliget</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Dazemep plus | Fantasmic plus | Glibetic | Glio P | Glitamap | Pio glee | Piobetic G | Pioglimp ds | Piotone gem | Piozer g | Poze G | Thiozer | Zoliget</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Pioglitazone and Glimepiride</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Tandemact</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Duetact</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Duetact</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Tandemact</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2">
<a name="ADA.2"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023.<i> Diabetes Care.</i> 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference">
                  American Diabetes Association (ADA). Standards of medical care in diabetes–2020. <i>Diabetes Care</i>. 2020;43(suppl 1):S1-S212. https://care.diabetesjournals.org/content/43/Supplement_1. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2021. <i>Diabetes Care</i>. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590212">
<a name="25590212"></a>Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline [published correction appears in <i>J Clin Endocrinol Metab</i>. 2015;100(5):2135-2136]. <i>J Clin Endocrinol Metab</i>. 2015;100(2):342-362. doi: 10.1210/jc.2014-3415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/25590212/pubmed" id="25590212" target="_blank">25590212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15303450">
<a name="15303450"></a>Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/15303450/pubmed" id="15303450" target="_blank">15303450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Duetact (pioglitazone/glimepiride) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America, Inc; June 2020.</div>
</li>
<li>
<div class="reference">
                  FDA Safety Alert. MedWatch. Pioglitazone-containing medicines: drug safety communication – updated FDA review, increased risk of bladder cancer. Food and Drug Administration website. Available at <a href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm532772.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery" target="_blank">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm532772.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery</a>. Accessed December 19, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9935017">
<a name="9935017"></a>Garratt KN, Brady PA, Hassinger NL, et al, “Sulfonylurea Drugs Increase Early Mortality in Patients With Diabetes Mellitus After Direct Angioplasty for Acute Myocardial Infarction,” <i>J Am Coll Cardiol</i>, 1999, 33(1):119-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/9935017/pubmed" id="9935017" target="_blank">9935017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644481">
<a name="15644481"></a>Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/15644481/pubmed" id="15644481" target="_blank">15644481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(supp 4):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi: 10.1038/ijo.2009.79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17905165">
<a name="17905165"></a>Lago RM, Singh PP, and Nesto RW, “Congestive Heart Failure and Cardiovascular Death in Patients with Prediabetes and Type 2 Diabetes Given Thiazolidinediones: A Meta-Analysis of Randomised Clinical Trials,” <i>Lancet</i>, 2007, 370 (9593):1129-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/17905165/pubmed" id="17905165" target="_blank">17905165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi: 10.1210/jc.2019-00198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17848652">
<a name="17848652"></a>Lincoff AM, Wolski K, Nicholls SJ, et al, “Pioglitazone an Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus,” <i>JAMA</i>, 2007, 298(10):1180-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/17848652/pubmed" id="17848652" target="_blank">17848652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160151">
<a name="23160151"></a>Melissas J, Leventi A, Klinaki I, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. <i>Ann Surg</i>. 2013;258(6):976-982. doi: 10.1097/SLA.0b013e3182774522.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/23160151/pubmed" id="23160151" target="_blank">23160151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27568471">
<a name="27568471"></a>Mingrone G, Cummings DE. Changes of insulin sensitivity and secretion after bariatric/metabolic surgery. <i>Surg Obes Relat Dis</i>. 2016;12(6):1199-1205. doi: 10.1016/j.soard.2016.05.013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/27568471/pubmed" id="27568471" target="_blank">27568471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12235454">
<a name="12235454"></a>Niemi M, Cascorbi I, Timm R, et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. <i>Clin Pharmacol Ther.</i> 2002;72(3):326-332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/12235454/pubmed" id="12235454" target="_blank">12235454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi: 10.1007/s11695-012-0622-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22312141">
<a name="22312141"></a>Qaseem A, Humphrey LL, Sweet DE, et al, “Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,” <i>Ann Intern Med</i>, 2012, 156(3):218-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/22312141/pubmed" id="22312141" target="_blank">22312141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31536101">
<a name="31536101"></a>Rosenstock J, Kahn SE, Johansen OE, et al; CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial [published online September 19, 2019; published correction appears in <i>JAMA</i>. 2019;322(21):2138]. <i>JAMA</i>. doi: 10.1001/jama.2019.13772.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/31536101/pubmed" id="31536101" target="_blank">31536101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415461">
<a name="16415461"></a>Simpson SH, Majumdar SR, Tsuyuki RT, et al, “Dose-Response Relation between Sulfonylurea Drugs and Mortality in Type 2 Diabetes Mellitus: A Population-Based Cohort Study,” <i>CMAJ</i>, 2006, 174(2):169-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/16415461/pubmed" id="16415461" target="_blank">16415461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16608888">
<a name="16608888"></a>Schwartz AV, Sellmeyer DE, Vittinghoff E, et al, “Thiazolidinedione Use and Bone Loss in Older Diabetic Adults,” <i>J Clin Endocrin Metab</i>, 2006, 91(9):3349-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/16608888/pubmed" id="16608888" target="_blank">16608888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242722">
<a name="15242722"></a>Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/15242722/pubmed" id="15242722" target="_blank">15242722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23222033">
<a name="23222033"></a>Tandra S, Chalasani N, Jones DR, Mattar S, Hall SD, Vuppalanchi R. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. <i>Ann Surg</i>. 2013;258(2):262-269. doi: 10.1097/SLA.0b013e31827a0e82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/23222033/pubmed" id="23222033" target="_blank">23222033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15373844">
<a name="15373844"></a>Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/15373844/pubmed" id="15373844" target="_blank">15373844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9742977">
<a name="9742977"></a>UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). <i>Lancet</i>. 1998;352(9131):854-865.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/9742977/pubmed" id="9742977" target="_blank">9742977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-992232">
<a name="992232"></a>University Group Diabetes Program, “A Study of the Effects of Hypoglycemia Agents of Vascular Complications in Patients with Adult-Onset Diabetes. VI. Supplementary Report on Nonfatal Events in Patients Treated with Tolbutamide,” <i>Diabetes</i>, 1976, 25(12):1129-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/992232/pubmed" id="992232" target="_blank">992232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17363747">
<a name="17363747"></a>Yaturu S, Bryant B, Jain SK, “Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men,” <i>Diabetes Care</i>, 2007, 30(6):1574-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-glimepiride-drug-information/abstract-text/17363747/pubmed" id="17363747" target="_blank">17363747</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9477 Version 238.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
